" class="no-js "lang="en-US"> SynHelix - Medtech Alert
Monday, August 11, 2025
SynHelix | Pharmtech Focus

SynHelix

About SynHelix

SynHelix

To meet the demands of the booming synthetic biology market, we need to develop a faster and more affordable DNA synthesis technology than the current market standard which is based on a complex chemical process and that is time-consuming, inefficient, with limited synthesis flexibility and requires toxic chemicals.
A rising need to disrupt industrial processes by synthetic biology resonates strongly and promises a burst of DNA synthesis demand.
SynHelix offers a unique proprietary enzyme-based DNA synthesis solution that promises a gigaprep-scale DNA production for life sciences laboratories and industries that need large amounts of DNA constructs for diverse applications such as cell and gene therapies, personalized diagnostics, DNA vaccines, biofuels and chemicals production, data storage technologies, …).

Related Story

Univercells Acquires SynHelix, Entering into Synthetic Biology and the Race to Next-generation DNA Synthesis

January 6 2022

Univercells S.A. (Univercells) today announces its acquisition of SynHelix, a biotechnology company that aims to debottleneck […]